Distribution of hepatitis B virus genotypes in patients with chronic hepatitis B in Turkey

Mustafa Sunbul, Hakan Leblebicioglu

Abstract

AIM: Hepatitis B virus (HBV) strains isolated worldwide have been classified into eight genomic groups deduced from genome comparisons and designated as genotypes A to H. We aimed to investigate prevalence of HBV genotypes and subtypes in Turkey.

METHODS: A total of 88 chronic hepatitis B (CHB) patients from 15 hospitals throughout the country were included. Patients who were HBsAg positive in serum at least for 6 mo, who had HBV-DNA in serum and elevation of ALT levels more than two times upper limit of normal, and who had percutaneous liver biopsy within 6 mo were included. Genotyping of HBV was done by restriction fragment length polymorphism (RFLP). The patients received subcutaneous 9 MU interferon-α 2a thrice a week for a period of 6 mo.

RESULTS: Genotype D was detected in 78 of 88 (88.7%) patients, however, genotyping failed in two patients (2.3%), while no product was obtained in eight (9.0%) patients. Regarding subtypes, D2 was more prevalent (67 patients between 78% and 85.9%) followed by subtype D2+deletion (seven patients of 78 or 8.9%), subtype D1 (three patients of 78 or 3.9%) and subtype D3 (one patient of 78 or 1.3%). Thirty-three patients (37.5%) were HBeAg positive compared to 55 (62.5%) anti-HBe positive patients. The endpoint for the viral response of HBeAg positive patients was 27.2%, while it was found 52.7% in HBeAg negative patients (P<0.05). Long-term persistent viral response was 29.5% for all patients.

CONCLUSION: This multi-center study indicates that the predominant genotype with CHB patients in Turkey like in other Mediterranean countries is genotype D.

© 2005 The WJG Press and Elsevier Inc. All rights reserved.

Key words: Chronic hepatitis B; Genotype; Interferon-α 2a
all patients except the ones with a previous liver biopsy within 6 mo. Those with malignancy, depression, anti-HIV positivity, cirrhosis, history of antiviral therapy and thyroid dysfunction, and pregnant women were excluded. Also patients who were positive for anti-HCV and anti-HDV were excluded.

**Biochemical and serological markers**

Liver biochemical tests, ALT (0-46 IU/L), aspartate aminotransferase (AST) (8-46 IU/L), and gamma-glutamyl-transpeptidase (GGT) (7-49 IU/L) were measured in all patients at initial examination, third, sixth months and during the follow-up at each institution. Serological markers HBsAg, hepatitis B e antigen (HBeAg), anti-HBe, anti-HBc IgM, anti-HBe IgG, anti-HBs, anti-HAV (IgM and IgG), anti-HCV and anti-HDV total (IgM+IgG) were tested during first evaluation by commercially available kits (Assym, Abbott Laboratories, North Chicago, IL, USA) at each institution.

**Determination of HBV genotypes**

Serum samples from each subject were taken at first examination and stored at -70 °C until they were studied. Patients' sera from other samples were transferred at approximately -15 °C into dry ice boxes. HBV-DNA was isolated with high pure viral nucleic acid kit (Roche Diagnostics, Mannheim, Germany) according to the instructions of the manufacturer. Briefly 200 µL sera were used for DNA extraction and 50 µL elution buffer was used for elution of DNA. Five microliters of HBV-DNA were added to a 45 µL reaction mixture for amplification. HBV primers (HBV-1 and HBV-2) described by Lindh et al[8], were obtained commercially. The sequences of PCR primers used in this study are shown in Table 1. PCR reaction mixture contained 200 µmol/L each primer, 1.5 mmol/L MgCl2 and 75 mmol/L Tris-HCl, 20 mmol/L (NH4)2SO4, and 0.25 µL Taq polymerase (5 U/µL, MBI Fermentas) to which a 50 µL reaction volume was added. Samples were thermocycled (MIR-D40 Sanyo) for 40 cycles (1 min at 94 °C, 1 min at 55 °C, 2 min at 72 °C). PCR products were separated in a 1.5% agarose gel, stained with ethidium bromide, and visualized under UV light. A result was considered positive when the band of the appropriate size (approximately 446 and 479 bp amplicon for genotype D and genotype A, respectively) was visible in the gel. Standard procedures for reducing contamination were strictly followed.

**RESULTS**

Demographic characteristics

The study included 88 patients with CHB, 59 (67%) male and 29 (33%) female. The mean age was 35±11 years. Of all the patients, 55 (62.5%) were HBsAg positive compared to 55 patients (62.5%) being anti-HBe positive. Of 33 HBeAg positive patients, 20 were males and 13 were females, while 39 of 55 anti-HBe positive patients were males and 16 were females. The demographic characteristics and laboratory features of HBeAg positive and anti-HBe positive patients are shown in Table 2.

**Genotype outcomes**

Genotype D was detected in 78 of 88 (85.9%) patients, however, genotyping failed in two patients (2.3%), while no PCR and HBV-DNA product was obtained in eight (9.0%) patients. Regarding subtypes, D2 was more prevalent (67

![Table 1 Primer sequences used for HBV genotyping by PCR-RFLP](#)

| Primer   | Sequence                        | Characteristics       |
|----------|---------------------------------|-----------------------|
| HBV-1    | 5’-TCACCATATTCTTGGGACACAGA-3’  | (nt 2823-2845, sense) |
| HBV-2    | 5’-TTCTGAACTGGACCCACCA-3’      | (nt 80-61, antisense) |

![Table 2 Baseline characteristics of HBeAg positive and anti-HBe positive patients (mean±SD)](#)

| Characteristics | HBeAg positive (n=55) | Anti-HBe positive (n=33) | Total (n=88) |
|-----------------|-----------------------|--------------------------|--------------|
| Age (yr)        | 30±10                 | 37±11                    | 35±11        |
| ALT             | 148±107               | 155±96                   | 151±94       |
| AST             | 98±90                 | 87±75                    | 93±71        |
| GGT             | 48.6±40.6             | 43.6±35.5                | 45.3±39.5    |
| Knodell score   | 7.3±3.4               | 7.6±3.2                  | 7.4±3.8      |

**Treatment schedule**

The interferon-α 2a (Roferon, Roche, Basel, Switzerland) 9 MU was subcutaneously given thrice a week for a period of 6 mo. Patients were assessed before the treatment, at 3 mo, at the end of the treatment and 6 mo after the discontinuation of therapy, and they all underwent a thorough physical examination, whole blood counts, urinary analysis as well as assessing their biochemical parameters and HBV-DNA. At 3 mo assays, the treatment was discontinued for patients with PCR HBV-DNA positivity. For those whose response was detected, treatment lasted to achieve the period of 6 mo.

**Criteria for response to therapy**

Response to interferon (IFN) therapy was evaluated in accordance with HBV-DNA clearance from serum (viral response), normalization of serum ALT levels (biochemical response) and HBeAg/anti-HBe seroconversion (serological response). After 6 mo of treatment, PCR HBV-DNA negative patients were defined as persistent long-term viral response. HBsAg clearance from serum was called complete response[5,8].

**Statistical analysis**

Data in the text and tables are expressed as mean±SD. Differences between groups were examined by χ² test, Fisher’s exact test, Bonferroni’s correction and Wilcoxon sign assay. A P value of less than 0.05 was considered to be significant.
patients among 78 or 85.9%) followed by subtype D2+deletion (seven patients of 78 or 8.9%), subtype D1 (three patients of 78 or 3.9%) and subtype D3 (one patient of 78 or 1.3%).

Assessment of response to therapy

ALT and AST values in patients before therapy and at months 3 and 6 during therapy and at month 6 after the treatment are given in Table 3.

Bonferroni’s correction and Wilcoxon sign assay were also performed for patients, whose ALT and AST values between pre-treatment, at third month, at sixth month and 6 mo after the therapy were found to be significantly different from Friedman variance analysis. It was found that there was a significant difference between the initial ALT value and values of 3, 6 and 12 mo. At third month, a viral response occurred in 53.4% of the patients. A total of 41 patients discontinued the treatment, 35 HBV-DNA positive patients along with six who failed to continue due to several reasons (two hyperthyroidism, two severe depression, one activated lung tuberculosis, and one interstitial lung disease development). Forty-seven patients who showed viral response at 3 mo were continued until 6 mo. Thirty-eight (43.1%) out of those patients who accomplished the treatment at 6 mo were PCR HBV-DNA negative compared to 9 (10.2%) positive. During the sixth month, 26 patients (29.5%) continued long-term persistent response, while eight patients (9.1%) developed relapse. Four patients did not come up for control. The viral, biochemical and serological responses of HBeAg and anti-HBe positive patients at 3, 6 and 12 mo (6 mo after the treatment) are listed in Table 4.

When viral response rates of months 3 and 6 were compared, the response rate in HBeAg negative patients group was higher than that in HBeAg positive patients (at 3 mo $P<0.01$, at 6 mo $P<0.05$). Long-term persistent response (viral response+biochemical response) was found to be 18.1% in HBeAg positive patients compared to 30.9% in HBeAg negative patients. Although the viral response rate was higher in HBeAg negative, the difference was not statistically significant ($P>0.5$). The long-term persistent response rate was 26.1% in all patients. During the course of the treatment, 24.2% of the HBeAg positive patients developed seroconversion. HBsAg was lost only in two (2.3%) patients, one developed anti-HBs and the other had no occurrence of anti-HBs during follow-up.

When the response rates were evaluated in accordance with the subtypes of genotype D, it was found that 85.9% of the patients had D2 subtype at the beginning of the treatment, while the genotype detected in 91.2% of the patients with persistent response is D2. No statistically significant difference was found ($P>0.5$). The genotype distribution before the treatment and for patients with long-term persistent response is shown in Table 5.

**DISCUSSION**

The success of CHB treatment depends on some parameters. It is higher in females as a gender who have lower HBV-DNA levels, higher ALT levels, moderate and severe hepatitis damages, whereas the response to treatment rate is lower in males with mild liver damage, higher HBV-DNA levels and lower ALT levels[15]. Recently, the relation between HBV genotype and treatment success has also been examined. Studies suggest that genotype C is associated with more severe liver damages compared to genotype B[16]. Kao et al[11], reported that the most prevalent genotypes in Thailand are B and C, and genotype C is associated with more severe liver damages, while genotype is mostly associated with HCC. In another study, 73 patients received IFN therapy, and 34 patients were registered as control group. Genotype B was determined in 38% of the patients compared to genotype C in 60%. The response rate in genotype B was significantly higher than that in genotype C[12]. In the present study patients from 15 medical centers throughout Turkey were included. Since all of the genotypes determined are genotype D, the relation between the severity of liver disease and genotype could not be evaluated. No statistically significant difference was found in subtypes between the pre-treatment patients and those with a persistent response ($P>0.5$). There are few reports in the literature on genotype study for patients with CHB in Turkey. Multi-center national study including the cases of acute viral hepatitis B, genotype D was determined in 147 of 158 patients, and genotyping failed in 11 cases[13]. Yalcin et al[16], also found genotype D in the 32 CHB patients and 12 inactive HBsAg carrier. These findings show that the prevalent genotype in patients with viral hepatitis B in

| Response outcome | Total | HBeAg positive | Anti-HBe positive | $P$ |
|------------------|-------|----------------|-------------------|-----|
| Viral response   |       |                |                   |     |
| $3^\text{rd}$ mo| 47    | 53.4           | 36.3              | $<0.01$ |
| $6^\text{th}$ mo| 36    | 43.1           | 27.2              | $<0.05$ |
| $12^\text{th}$ mo| 26   | 29.5           | 18.1              | $>0.1$ |
| Biochemical response |       |                |                   |     |
| $3^\text{rd}$ mo| 30   | 34.1           | 21.2              | $>0.5$ |
| $6^\text{th}$ mo| 26   | 29.5           | 24.2              | $>0.5$ |
| $12^\text{th}$ mo| 25  | 28.4           | 24.2              | $>0.5$ |
| Serological response |       |                |                   |     |
| $3^\text{rd}$ mo| 4    | 12.1           | 12.1              | $=$  |
| $6^\text{th}$ mo| 7    | 21.2           | 21.2              | $=$  |
| $12^\text{th}$ mo| 8   | 24.2           | 24.2              | $=$  |

**Table 3 ALT and AST values pre-treatment, during and post-treatment (mean±SD)**

| Time Point                      | ALT (mean±SD) | AST (mean±SD) |
|--------------------------------|----------------|---------------|
| Pre-treatment                  | 135.0±96.0     | 87.0±75.0     |
| $3^\text{rd}$ mo              | 56.8±20.1      | 40.6±11.9     |
| $6^\text{th}$ mo              | 62.3±38.7      | 53.3±17.4     |
| $6^\text{th}$ mo after therapy| 43.3±23.0      | 35.2±19.4     |

**Table 5 Subtype of genotype distribution in patients**

| Subtype of genotype | Pre-treatment ($n=78$) | Patients who completed the treatment ($n=31$) | Non-responder ($n=47$) |
|---------------------|------------------------|---------------------------------------------|------------------------|
|                     | $n$ Percentage          | $n$ Percentage                              | $n$ Percentage          |
| D2                  | 67 85.9                | 29 93.5                                     | 38 80.9                |
| D2+deletion         | 7 8.9                  | 2 6.5                                       | 5 10.6                 |
| D1                  | 3 3.9                  | -                                           | 3 6.4                  |
| D3                  | 1 1.3                  | -                                           | 1 2.1                  |
our country is genotype D. Interferons have antiviral, immunomodulatory and antiproliferative effects\[^{[3]}\]. Interferon-α is the primary antiviral agent used in the treatment of CHB patients. In a meta-analysis of 24 studies by Craxi et al\[^{[4]}\], the effect of interferon was evaluated on HBeAg positive CHB patients. Six to twelve months after treatment with interferon, persistent ALT normalization was 26.2%, HBeAg deletion was 24.3%, persistent HBV-DNA negativity was 23.4% and HBsAg negativity was 5.6%. The persistent viral response ranged from 15% to 40%\[^{[5]}\]. The recommended dosage for IFN is 9-10 million s.c. thrice a week for a period of 4-6 mo\[^{[6]}\].

In our study the response to IFN was 53.4% for all patients at 3\(^{rd}\) mo, 43.1% at 6\(^{th}\) mo and 29.5% at 12\(^{th}\) mo (6 mo after the end of therapy). It has been reported that, with IFN monotherapy, the development rate for HBeAg seroconversion is approximately 20-30%\[^{[7]}\]. HBeAg seroconversion was 12.1% at 3\(^{rd}\) mo, 9.1% at 6\(^{th}\) mo and 3.0% at 12\(^{th}\) mo and 24.2% in total. HBeAg deletion was around 8% in average as a result of treatment in CHB patients. Such cases are called complete response\[^{[8]}\]. We had complete response in 2.3% of our patients.

Mutation is possible in various sections of HBV genome. The most common is the mutation in precore region (G1896A), and HBeAg cannot be synthesized in such mutants. The persistent response to interferon is lower in precore mutant CHB patients compared to “wild type” HBV patients. One of the reasons is spontaneous seroconversion of HBeAg in some patients, which is facilitated by IFN. Some studies demonstrated that HBV genotype may influence HBeAg seroconversion. Patients with genotype C have lower rates of spontaneous HBeAg seroconversion and high cirrhosis than genotype B patients\[^{[2,21,22]}\]. It has been reported that the response rate is higher in genotype A and B patients treated with interferon compared to genotype D and C patients\[^{[11,23]}\]. These data will obligate the organization of clinical trials for antiviral therapies to be based on genotypes in the future.

HBeAg negative disease accounts for up to 30% of CHB globally\[^{[24]}\]. Prevalence of precore mutants vary depending on the geographical regions; it is common in the Mediterranean countries and Asia, whereas very rare in North America and Western Europe. This variation may be associated with prevalent HBV genotype because these mutants are only present in patients infected with HBV genotypes B-D. Recently many investigators in Europe have assumed that CHB patients with HBeAg negativity are more than HBeAg positive patients\[^{[25]}\]. Prevalence rates in the Mediterranean region (Italy, Greece and Israel) are approximately 50-80%, with 40-55% in East Asia (Hong Kong, Taiwan and China) and at least 15% in South Asia (India)\[^{[26]}\]. Seroprevalence data show that from 1975 to 1985, 58% of 584 chronically infected Italian patients studied were HBeAg positive, while 42% were HBeAg negative. However, from 1992 to 1997, HBeAg positive disease made up only 10% of the 834 CHB patients studied. The remaining 90% were HBeAg negative and/or anti-HBe antibody positive\[^{[27]}\]. In the present study, 62.5% of our patients were precore mutant. In a previous multi-center study, it was found to be 54.2% and response to IFN therapy was significantly higher in precore mutants compared to HBeAg positive patients\[^{[28]}\]. These findings also suggest that CHB patients in Turkey are mostly precore mutants. It has been reported that HBeAg positive cases and precore mutant cases provide distinct responses to IFN therapy\[^{[29,30]}\]. In our study, the long-term persistent viral response was 18.1% in HBeAg positive cases, while it was found to be 36.3% in precore mutants. The persistent viral response was 29.5% in all patients. Although long-term persistent response was higher in precore mutants compared to HBeAg positive patients, the difference between them was not statistically significant (P>0.5).

In conclusion, this multi-center study indicates that the predominant genotype with CHB patients in Turkey like in other Mediterranean countries is genotype D. Precore mutants are prevalent among patients with CHB in Turkey as well. A higher response was obtained although the persistent viral response to IFN therapy was not statistically significant in terms of HBeAg positive CHB.

ACKNOWLEDGMENT

Hepatitis Study Group: Gurbuz Y, Tutuncu E, Diskapi (Ankara), Caylan R, Koskai I (Trabzon), Ozgenc O, Inan N (Izmir), Yildiz O, Aygen B (Kayseri), Usluer G (Eskişehir), Ayaz C (Diyarbakir), Ergolu C, Esen S, Turan D (Samsun), Bektas A (Samsun), Irmak H (Van), Sirmatel F (Gaziantep), Tulek N (Ankara), Sencan I (Duzce), Dokmetas I (Sivas), Kaygusuz S (Kirikkale), Saltoglu N (Adana), Akcam Z (Isparta), Turkey.

REFERENCES

1. Mbayed VA, Lopez JL, Telenta PF, Palacios G, Badia I, Ferro A, Galoppo C, Campos R. Distribution of hepatitis B virus genotypes in two different pediatric populations from Argentina. J Clin Microbiol 1998; 36: 3362-3365
2. Chu CJ, Lok AS. Clinical significance of hepatitis B virus genotypes. Hepatology 2002; 35: 1274-1276
3. Ortilo E, Ichida T, Sakugawa H, Sata M, Horike N, Hino K, Okita K, Okanoue T, Inou S, Tanaka E, Suzuki K, Watanabe H, Higo S, Mizokami M. Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 2001; 34: 590-594
4. Conjevaram HS, Lok AS. Management of chronic hepatitis B. J Hepatol 2003; 38 Suppl 1: S90-S103
5. Chir R, Locarnini S. Treatment of chronic hepatitis B: current challenges and future directions. Rev Med Virol 2003; 13: 255-272
6. Lai CL, Ratziu V, Yuen MF, Poyntard T. Viral hepatitis B. Lancet 2003; 362: 2089-2094
7. Lindh M, Gonzalez JE, Norkrans G, Horal P. Genotyping of hepatitis B virus by restriction pattern analysis of a pre-S amplicon. J Virol Methods 1998; 72: 163-174
8. Esteban R. Management of chronic hepatitis B: an overview. Semin Liver Dis 2002; 22 Suppl 1: 1-6
9. Yuen MF, Lai CL. Treatment of chronic hepatitis B. Lancet Infect Dis 2001; 1: 232-241
10. Lindh M, Hannoun C, Dhillon AP, Norkrans G, Horal P. Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. J Infect Dis 1999; 179: 775-782
11. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000; 33: 998-1002
12. Wai CT, Chu CJ, Hussain M, Lok AS. HBV genotype B is associated with better response to interferon therapy in HBeAg positive CHB.

Sunbul M et al. Distribution of genotype chronic hepatitis B in Turkey 1979
chronic hepatitis than genotype C. *Hepatology* 2002; **36**: 1425-1430

13. **Leblebicioglu H**, Eroglu C. Acute hepatitis B virus infection in Turkey: epidemiology and genotype distribution. *Clin Microbiol Infect* 2004; **10**: 537-541

14. **Yalcin K**, Degertekin H, Bahcecioglu IH, Demir A, Aladag M, Yildirim B, Horasanli S, Ciftci S, Badur S. Hepatitis B virus genotype D prevails in patients with persistently elevated or normal ALT levels in Turkey. *Infection* 2004; **32**: 24-29

15. **Thomas H**, Foster G, Platix D. Mechanisms of action of interferon and nucleoside analogues. *J Hepatol* 2003; **39 Suppl 1**: S93-S98

16. **Craxi A**, Di Bona D, Camma C. Interferon-alpha for HBeAg-negative chronic hepatitis B. *J Hepatol* 2003; **39 Suppl 1**: S99-S105

17. **Trepo C**, Maynard M, Zoulim F. Perspectives on therapy of hepatitis B. *J Hepatol* 2003; **39 Suppl 1**: S220-S223

18. **Lee WM**. Hepatitis B virus infection. *N Engl J Med* 1997; **337**: 1733-1745

19. **Yuen MF**, Lai CL. Current and future antiviral agents for chronic hepatitis B. *J Hepatol* 2003; **39 Suppl 1**: S220-S223

20. **Hoofnagle JH**. Challenges in therapy of chronic hepatitis B. *J Hepatol* 2003; **39 Suppl 1**: S220-S223

21. **Chu CJ**, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. *Gastroenterology* 2002; **122**: 1756-1762

22. **Kao JH**, Chen PJ, Lai MY, Chen DS. Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. *J Clin Microbiol* 2002; **40**: 1207-1209

23. **Zhang X**, Zoulim F, Habersetzer F, Xiong S, Trepo C. Analysis of hepatitis B virus genotypes and precore region variability during interferon treatment of HBe antigen negative chronic hepatitis B. *J Med Virol* 1996; **48**: 8-16

24. **Schalm SW**, Thomas HC, Hadziyannis SJ. Chronic hepatitis B. *Prog Liver Dis* 1990; **9**: 443-462

25. **Lok AS**. Hepatitis B infection: pathogenesis and management. *J Hepatol* 2000; **32**(Suppl 1): 89-97

26. **Rizzetto M**, Volpes R, Smedile A. Response of pre-core mutant chronic hepatitis B infection to lamivudine. *J Med Virol* 2000; **61**: 398-402

27. **Sunbul M**, Leblebicioglu H, Koksal I, Aygen B, Akbulut A, Hosoglu S, Dokmetas I, Ulusoy S. The response to interferon therapy of hepatitis B infections caused by precore. *Viral Hepatit Dergisi* 2001; **2**: 286-289

28. **Sunbul M**, Leblebicioglu H, Koksal I, Aygen B, Akbulut A, Hosoglu S, Dokmetas I, Ulusoy S. The response to interferon therapy of hepatitis B infections caused by precore. *Viral Hepatit Dergisi* 2001; **2**: 286-289

29. **Norder H**, Hammas B, Lee SD, Bile K, Courouce AM, Mushahwar IK, Magnus LO. Genetic relatedness of hepatitis B viral strains of diverse geographical origin and natural variations in the primary structure of the surface antigen. *J Gen Virol* 1995; **74** ( Pt 7): 1341-1348

30. **Lindh M**, Andersson AS, Gusdal A. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus-large-scale analysis using a new genotyping method. *J Infect Dis* 1997; **175**: 1285-1293

31. **Trevisani F**, D’Intino PE, Grazi GL, Caraceni P, Gasbarrini A, Colantoni A, Stefanini GF, Mazzetti A, Gazzetti G, Gasbarrini G, Bernardi M. Clinical and pathologic features of hepatocellular carcinoma in young and older Italian patients. *Cancer* 1996; **77**: 2223-2232

---

Science Editor Guo SY  Language Editor Elsevier HK